Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 11Active not recruiting 8Terminated 5Not yet recruiting 3Temporarily not available 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 1Leukemia, Myeloid 1Hodgkin Disease 1

Interventions

Specimen Handling 21Magnetic Resonance Spectroscopy 17Carboplatin 16Gemcitabine 14pembrolizumab 11Paclitaxel 11Cisplatin 11Interviews as Topic 10Injections 10fludarabine 9Radiotherapy 8Oxaliplatin 8Nivolumab 8Dexamethasone 8Cyclophosphamide 8Irinotecan 7Fluorouracil 7Bortezomib 7Biopsy 7Bevacizumab 7toripalimab 6Radiosurgery 5Pemetrexed 5Leucovorin 5Capecitabine 5130-nm albumin-bound paclitaxel 5trastuzumab deruxtecan 4liposomal doxorubicin 4cemiplimab 4X-Rays 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × fludarabine phosphate × 30 days × Clear all
NCT07164469 2026-06-05

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
100 enrolled
Lymphoid

Hodgkin Disease

NCT04579523 2026-06-04

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Not yet recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡